Endometrial and Cervical Cancer Treatments

Circulating Immune Profiling Reveals Immune Signatures Associated with Disease Stage and Outcome in Endometrial Cancer

This study identifies immune signatures in circulating blood linked to disease stage and prognosis in endometrial cancer using flow cytometry.

Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer

This study establishes a PDX and PDC platform to identify therapeutic vulnerabilities in endometrial cancer, revealing that epigenetic combination therapies show significant antitumor activity.

Endometrial cancer survival disparities in women of African ancestry persist beyond clinical, molecular, and socioeconomic determinants

This study examines endometrial cancer survival disparities between Black and White women, finding that African ancestry is independently associated with worse progression-free survival after adjusting for socioeconomic, clinical, and molecular factors.

Auranofin potentiates cisplatin response through context-dependent NOTCH-associated signaling states in endometrial cancer

This study shows auranofin enhances cisplatin response in endometrial cancer by modulating NOTCH signaling, with context-dependent effects on tumor models.

Comprehensive Molecular Characterization of High-Grade Endometrial Cancer in an Ancestrally-Diverse Cohort

This study characterizes the molecular differences in high-grade endometrial cancer across an ancestrally diverse cohort, identifying ancestry-associated mutations and immune microenvironment differences.

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.

Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer

This study shows that LARP1 promotes endometrial cancer survival and chemotherapy resistance by regulating E2F1 and suppressing apoptosis, and targeting LARP1 enhances carboplatin sensitivity.

Explainable Machine Learning for Preoperative Relapse Prediction in Molecularly Stratified Endometrial Cancer: A Single-Center Finnish Cohort Study

This paper develops explainable machine learning models to predict relapse timing in endometrial cancer using preoperative data, finding high performance with F1 scores up to 0.895.

RB1 gene mutations and their association with Endometrial Cancer

The paper investigates RB1 mutations in endometrial cancer, finding higher prevalence in younger patients and linking RB1 mutations to HPV infection pathways.

Interpretable prognostic modeling of endometrial cancer

This study compares Cox proportional hazards and optimal survival tree models for prognostic modeling of endometrial cancer using clinical and molecular data, finding linear models better for clinical features alone and tree models better with molecular data.

Genomic analysis of patient-derived xenograft models reveals intra-tumor heterogeneity in endometrial cancer and can predict tumor growth inhibition with talazoparib

The paper develops endometrial cancer PDX models that capture tumor heterogeneity and predict response to talazoparib.